Delinia

Delinia is a developer of therapies for autoimmune and inflammatory diseases. Delinia's main investigational new drug, DEL106, primarily targets autoimmune system diseases. Delinia’s leading project is a targeted regulatory T cell (Treg) therapy, which has the potential to selectively treat immune diseases without broadly suppressing the patient’s immune system.